1.Use of multiplex molecular respiratory panel in COVID-19 patients with suspected co-infections Insights and considerations in results interpretation
Nawi A.S. ; Engku Abd Rahman E.N.S. ; Nik Zuraina N.M.N. ; Musa N. ; Salleh M.Z. ; Samsudin M.N.F. ; Chua W.C. ; Muhd Besari A. ; Hassan R. ; Chan Y.Y.
Tropical Biomedicine 2025;42(No. 1):21-26
As critically ill COVID-19 patients are prone to infections by other respiratory pathogens, this study aimed
to investigate the detection of respiratory co-pathogens in such patients, by employing a multiplex
respiratory molecular panel. Conducted at Universiti Sains Malaysia Specialist Hospital (HPUSM) from
November 1, 2021, to November 1, 2022, this retrospective cross-sectional study analysed adults
admitted with confirmed COVID-19. Oropharyngeal/ nasopharyngeal swabs collected upon admission
were tested using the Fast Track Diagnostic (FTD®) Respiratory Pathogens 33 multiplex kit to detect
other respiratory pathogens. Within 48 hours of admission, the presence and type of organisms were
determined to assess community co-infections. Among 48 critically ill COVID-19 patients (26 male; mean
age, 62.2 years), clinically significant organisms were found in 32 patients (67%). Bacterial co-infections
or co-colonization were detected in 91% (29/32) of these patients, with Klebsiella pneumoniae (40%) and
Staphylococcus aureus (23%) were the most common, followed by Streptococcus pneumoniae (11%),
Moraxella catarrhalis (4%), and Haemophilus influenzae (2%). Fungal (6%) and viral (2%) co-infections
were less frequent. The use of syndromic respiratory panel in critically ill COVID-19 patients offers the
advantage of being highly sensitive, rapid, and able to detect multiple pathogens. However, detection of
multiple respiratory pathogens needs to be interpreted with caution, taking into consideration patient’s
clinical and radiological findings, as well as quantitative molecular data.


Result Analysis
Print
Save
E-mail